A multi-center, open-label, randomized, parallel-controlled phase Ⅱ study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera?) in patients with CD20-positive B-cell non-Hodgkin lymphoma

机标关键词：non-hodgkin、parallel、rituximab、dynamics、lymphoma、study、safety、phase、with、b-cell

所属期刊栏目：34

分类号：R739.62;TP273;TP311.138OR

在线出版日期：2023-04-21（万方平台首次上网日期，不代表论文的发表时间）

页数：共11页

页码：601-611